research use only

GSK2982772 RIP kinase inhibitor

Name: GSK2982772
Brand: Selleck Chemicals
SKU: S8484
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S8484

GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. It has exquisite kinase specificity and excellent activity in blocking many TNF-dependent cellular responses.

Chemical Structure

Molecular Weight: 377.40

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S848401 DMSO]75 mg/mL]false]Ethanol]30 mg/mL]false]Water]Insoluble]false Purity: 99.06%

99.06

Related Targets	Apoptosis related Ras STAT TNF-alpha Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 c-RET MDM2/MDMX Myc Antifolate MRP IAP OXPHOS PERK FKBP Thymidylate Synthase ABC Transporter Heme Oxygenase PFKFB Pyroptosis Photosensitizer PKD Survivin Annexin A ASK Bcl-6 Nur77
Related Products	Necrostatin-1 (Nec-1) GSK872 Necrostatin 2 racemate (Nec-1s) Mito-TEMPO RIPA-56 GSK'963 GSK583 GSK2983559 (compound 3) Resibufogenin GSK'547 ICCB-19 hydrochloride HS-1371 GSK481 RIP3 Antibody [J24B17] GSK2983559 active metabolite RIP Antibody [N10M19] RIP Antibody [P3C6] PK68 GSK-872 hydrochloride RIP3 Antibody [H22B6] GSK3145095 RIP2 Antibody [M23E23] Phospho-RIP3 (Ser232) Antibody [E19K17] Necrostatin-34 (Nec-34) Oditrasertib RIPK1-IN-7 OD36 GSK-843

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
insect cells	Function assay	1 hr	Inhibition of human RIP1 (1 to 375 residues) expressed in baculovirus infected insect cells preincubated for 1 hr followed by ATP addition measured after 5 hrs by ADP-Glo luminescence assay, IC50 = 0.001 μM.	28151659
U937	Function assay	24 hrs	Inhibition of RIP1 in human U937 cells assessed as reduction in TNFalpha/QVD-Oph-induced necrosis after 24 hrs by Cell Titer-Glo luminescent cell viability assay, IC50 = 0.0063 μM.	28151659
L929	Function assay	24 hrs	Inhibition of RIP1 in mouse L929 cells assessed as reduction in TNFalpha/QVD-Oph-induced necrosis after 24 hrs by Cell Titer-Glo luminescent cell viability assay, IC50 = 1.3 μM.	28151659
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	377.40	Formula	C₂₀H₁₉N₅O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1622848-92-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CN1C2=CC=CC=C2OCC(C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4

Solubility

In vitro
Batch:

DMSO : 75 mg/mL (198.72 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 30 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.750mg/ml (9.94mM)	Taking the 1 mL working solution as an example, add 50 μL of 75 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.625mg/ml (1.66mM)	Taking the 1 mL working solution as an example, add 50 μL of 12.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	human RIP1 ^[1] (Cell-free assay) 16 nM
In vitro	This compound has excellent activity in both RIP1 cellular systems, preventing TNF induced necrotic cell death, and an ulcerative colitis explant assay blocking spontaneous cytokine release^[1].
In vivo	GSK2982772 exhibits approximately equivalent RIP1 FP potency against human and monkey RIP1 but was significantly less potent against nonprimate RIP1. This compound displays a good free fraction in blood in rats (4.2%), dogs (11%), cynomolgus monkeys (11%), and humans (7.4%). The inhibitor has a good pharmacokinetic profile across both rats and monkeys. It distributes into a range of tissues including the colon, liver, kidney, and heart at concentrations comparable to those of blood. However, it has low brain penetration in rat (4%) despite possessing good cell permeability, which is likely due to active extrusion of this chemical from the brain via the efflux drug transporter. It is predicted that this compound has high bioavailability, moderate to low clearance with a moderate volume, and a terminal half-life in the order of 12 h^[1].
References	[1] https://pubmed.ncbi.nlm.nih.gov/28151659/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03590613	Completed	Autoimmune Diseases	GlaxoSmithKline	July 19 2018	Phase 1
NCT03305419	Completed	Autoimmune Diseases	GlaxoSmithKline	October 11 2017	Phase 1
NCT02903966	Completed	Colitis Ulcerative	GlaxoSmithKline	November 15 2016	Phase 2
NCT02858492	Completed	Arthritis Rheumatoid	GlaxoSmithKline	October 17 2016	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):